Table 6.

Currently available biologics: indications and adverse effects.

Medication	Use	Adverse Effects
Anti-IgE (omalizumab, SC, ≥6 years)	An add-on option for patients with severe allergic asthma uncontrolled on high dose ICS-LABA. elf-administration may be permitted	Reactions at the site of injection are common but minor. Anaphylaxis is rare.
Anti-IL5/anti-IL5R (anti-IL5 mepolizumab (SC, ≥12 or ≥6 years), reslizumab (IV, ≥18 years) or anti-IL5 receptor benralizumab (SC, ≥12 years))	Add-on options for patients with severe eosinophilic asthma uncontrolled on high dose ICS-LABA	Headache and reactions at injection site are common but minor.
Anti-IL4R (dupilumab, SC, ≥12 years)	An add-on option for patients with severe eosinophilic/Type 2 asthma uncontrolled on high dose ICS-LABA, or requiring maintenance OCS. It is also approved for treatment of moderate-severe atopic dermatitis. Self-administration may be permitted	Reactions at injection site are common but minor. Blood eosinophilia occurs in 4–13% of patients.